INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Corporate insider
GK

Guarini Kathryn

DirectorCIK 0001992352

EDGAR filingsOpen in network
Disclosed transactions11
Buys / sells0 / 3
Max Insider Score25
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
13
GK
Guarini KathrynDirector
REGNREGENERON PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M$288K
400 sh
Oct 30, 2026Nov 3, 2026
traded Oct 30, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    REGENERON PHARMACEUTICALS, INC.Director · Jan 6, 2026
7
GK
Guarini KathrynDirector
REGNREGENERON PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M
—
400 sh
Oct 30, 2026
Nov 3, 2026
traded Oct 30, 2026
+4d
SEC FORM 4

Evidence

25
GK
Guarini KathrynDirector
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$360K
400 sh
Oct 30, 2026Nov 3, 2026
traded Oct 30, 2026
+4dSEC FORM 4

Evidence

13
GK
Guarini KathrynDirector
REGNREGENERON PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M$288K
400 sh
Sep 2, 2026Sep 3, 2026
traded Sep 2, 2026
+1dSEC FORM 4

Evidence

15
GK
Guarini KathrynDirector
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$340K
400 sh
Sep 2, 2026Sep 3, 2026
traded Sep 2, 2026
+1dSEC FORM 4

Evidence

7
GK
Guarini KathrynDirector
REGNREGENERON PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M—
400 sh
Sep 2, 2026Sep 3, 2026
traded Sep 2, 2026
+1dSEC FORM 4

Evidence

19
GK
Guarini KathrynDirector
REGNREGENERON PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$320K
400 sh
Aug 10, 2026Aug 12, 2026
traded Aug 10, 2026
+2dSEC FORM 4

Evidence

7
GK
Guarini KathrynDirector
REGNREGENERON PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M—
400 sh
Aug 10, 2026Aug 12, 2026
traded Aug 10, 2026
+2dSEC FORM 4

Evidence

17
GK
Guarini KathrynDirector
REGNREGENERON PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M$288K
400 sh
Aug 10, 2026Aug 12, 2026
traded Aug 10, 2026
+2dSEC FORM 4

Evidence

9
GK
Guarini KathrynDirector
REGNREGENERON PHARMACEUTICALS, INC.
Grant or award
A—
1,962 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence

17
GK
Guarini KathrynDirector
REGNREGENERON PHARMACEUTICALS, INC.
Grant or award
A—
155 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence